The EUTOS prognostic score: review and validation in 1288 patients with CML treated frontline with imatinib
The EUTOS prognostic score: review and validation in 1288 patients with CML treated frontline with imatinib
复制标题
DOI：
10.1038/leu.2013.171
复制
发表时间：
2013-10-01
期刊：
影响因子：
11.4
通讯作者：
Pfirrmann, M.
中科院分区：
文献类型：
--
作者：
Hoffmann, V. S.;Baccarani, M.;Pfirrmann, M.
酪氨酸激酶抑制剂（TKI）在费城染色体阳性（Ph_）慢性粒细胞白血病（CML）治疗中的引入彻底改变了治疗结果，但该疾病的预后仍然基于传统化疗和干扰素（IFN）-α时代开发的预后系统。开发了一种新的预后评分，仅包括两个变量：脾脏大小和嗜碱性粒细胞，用于预测完全细胞遗传学反应（CCyR）和无进展生存期（PFS）。该评分基于参加一线伊马替尼治疗前瞻性多中心研究的大量患者。 EUTOS（欧洲 CML 治疗和结果研究）评分的预后价值现已在一项独立、多中心、跨国系列中进行了测试，该系列由 1288 名在前瞻性研究之外接受伊马替尼一线治疗的患者组成。研究发现，在这些患者中，EUTOS 预后评分也可预测 CCyR、PFS 和总生存期 (OS)。此外，据报道，在欧洲、美洲和亚洲进行的另外 8 项独立研究中，有 7 项对近 2000 名患者进行的评分具有显着的预后价值。 EUTOS 风险评分是预测 TKI（尤其是伊马替尼）疗效的有效工具。
The introduction of tyrosine kinase inhibitors (TKI) in the treatment of Philadelphia chromosome-positive (Ph_) chronic myeloid leukemia (CML) has revolutionized the outcome, but the prognosis of the disease is still based on prognostic systems that were developed in the era of conventional chemotherapy and interferon (IFN)-alfa. A new prognostic score including only two variables, spleen size and basophils, was developed for the prediction of complete cytogenetic response (CCyR) and progression-free survival (PFS). The score was based on a large series of patients who were enrolled in prospective multicenter studies of first-line imatinib treatment. The prognostic value of the EUTOS (European Treatment and Outcome Study for CML) score has now been tested in an independent, multicenter, multinational series of 1288 patients who were treated first-line with imatinib outside prospective studies. It was found that also in these patients, the EUTOS prognostic score was predictive for CCyR, PFS and overall survival (OS). In addition, the prognostic value of the score was reported to be significant in seven of the eight other independent studies of almost 2000 patients that were performed in Europe, the Americas and Asia. The EUTOS risk score is a valid tool for the prediction of the therapeutic effects of TKI, particularly imatinib.